Guggenheim lowered the firm’s price target on Merck to $127 from $128 and keeps a Buy rating on the shares ahead of the company announcing Q3 results on Thursday, October 26. The firm expects “another strong quarter” for both Keytruda and Gardasil, but notes that growth comps are “more challenging.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK:
- Kineta announces first patient dosed in Phase 1/2 VISTA-101 trial of KVA12123
- Merck receives positive EU CHMP opinion for PREVYMIS
- FDA approves Merck’s Keytruda for treatment of resectable NSCLC
- Merck (NYSE:MRK) Urges UK Government to Support Pharma
- Merck: EC approves KEYTRUDA as adjuvant treatment for NSCLC